Relutrigine

Relutrigine
Clinical data
Other namesPRAX-562; PRAX562
Routes of
administration		Oral
Drug classSodium channel blocker; Anticonvulsant
Identifiers
  • 3-[ethoxy(difluoro)methyl]-6-[5-fluoro-6-(2,2,2-trifluoroethoxy)-3-pyridinyl]-[1,2,4]triazolo[4,3-a]pyrazine
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC15H11F6N5O2
Molar mass407.276 g·mol−1
3D model (JSmol)
  • CCOC(C1=NN=C2N1C=C(N=C2)C3=CC(=C(N=C3)OCC(F)(F)F)F)(F)F
  • InChI=1S/C15H11F6N5O2/c1-2-28-15(20,21)13-25-24-11-5-22-10(6-26(11)13)8-3-9(16)12(23-4-8)27-7-14(17,18)19/h3-6H,2,7H2,1H3
  • Key:BFXBSYMVTNEFRF-UHFFFAOYSA-N

Relutrigine (INNTooltip International Nonproprietary Name; developmental code name PRAX-562) is a persistent neuronal sodium channel blocker which is under development for the treatment of epilepsy and headache. It is taken orally. The drug shows anticonvulsant effects in animals but with improved tolerability compared to existing sodium channel blockers. Relutrigine is under development by Praxis Precision Medicines. As of May 2026, it is in preregistration for epilepsy. Conversely, no recent development has been reported for headaches.

See also

References

  1. 1 2 3 4 5 6 "Praxis-Precision-Medicines". AdisInsight. 19 May 2026. Retrieved 6 June 2026.
  2. 1 2 3 Müller P, Draguhn A, Egorov AV (October 2024). "Persistent sodium currents in neurons: potential mechanisms and pharmacological blockers". Pflugers Archiv. 476 (10): 1445–1473. doi:10.1007/s00424-024-02980-7. PMC 11381486. PMID 38967655.
  3. 1 2 Kahlig KM, Scott L, Hatch RJ, Griffin A, Martinez Botella G, Hughes ZA, et al. (March 2022). "The novel persistent sodium current inhibitor PRAX-562 has potent anticonvulsant activity with improved protective index relative to standard of care sodium channel blockers". Epilepsia. 63 (3): 697–708. doi:10.1111/epi.17149. PMC 9304232. PMID 35037706.